Business Description
Cognition Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US19243B1026
Description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 24.17 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -44.7 | |||||
| 3-Year EPS without NRI Growth Rate | -32.5 | |||||
| 3-Year FCF Growth Rate | -49.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.14 | |||||
| 9-Day RSI | 43.09 | |||||
| 14-Day RSI | 45.21 | |||||
| 6-1 Month Momentum % | 40.31 | |||||
| 12-1 Month Momentum % | 5.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.37 | |||||
| Quick Ratio | 3.37 | |||||
| Cash Ratio | 2.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.6 | |||||
| Shareholder Yield % | -7.23 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -78.71 | |||||
| ROA % | -60.26 | |||||
| ROIC % | -505.24 | |||||
| ROC (Joel Greenblatt) % | -2589.05 | |||||
| ROCE % | -74.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.63 | |||||
| Price-to-Tangible-Book | 2.63 | |||||
| EV-to-EBIT | -1.7 | |||||
| EV-to-EBITDA | -1.72 | |||||
| EV-to-FCF | -2.71 | |||||
| Price-to-Net-Current-Asset-Value | 2.74 | |||||
| Price-to-Net-Cash | 3.33 | |||||
| Earnings Yield (Greenblatt) % | -58.82 | |||||
| FCF Yield % | -20.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cognition Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.86 | ||
| Beta | 0 | ||
| Volatility % | 82.79 | ||
| 14-Day RSI | 45.21 | ||
| 14-Day ATR ($) | 0.134776 | ||
| 20-Day SMA ($) | 1.916 | ||
| 12-1 Month Momentum % | 5.23 | ||
| 52-Week Range ($) | 0.9001 - 3.49 | ||
| Shares Outstanding (Mil) | 39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cognition Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cognition Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cognition Therapeutics Inc Frequently Asked Questions
What is Cognition Therapeutics Inc(CGTX)'s stock price today?
The current price of CGTX is $2.00. The 52 week high of CGTX is $3.49 and 52 week low is $0.90.
When is next earnings date of Cognition Therapeutics Inc(CGTX)?
The next earnings date of Cognition Therapeutics Inc(CGTX) is 2024-05-03 Est..
Does Cognition Therapeutics Inc(CGTX) pay dividends? If so, how much?
Cognition Therapeutics Inc(CGTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers